Amgen CEO, Keven Sharer (photo [1]), said yesterday that he does not foresee the company collaborating with anyone else to market its osteoporosis drug, denosumab, which is still in development.
Sharer said he could not see a potential benefit of collaborating with another U.S. company at this time, but others had suspected that Amgen might seek out a partner, since the company has limited expertise in the primary care market--the chief market for the drug. Still, "It is very hard for me to imagine what another company would bring to us," Sharer said.
Amgen will release additional study data next week, including comparison data with potential future rival Fosamax (made by Merck), and those data will likely pave the path for prospective partnership decisions moving forward.
- read the story [2] at the Wall Street Journal
- find out more [3] at CNN Money
Related Articles:
Denosumab--Next gen biotech blockbusters [4]
Amgen's D-mab posts positive in late-stage trial [5]
Amgen's D-mab meets trial goal [6]
Denosumab: Amgen's salvation? [7]
Links:
[1] http://www.fiercebiotech.com/special-reports/amgen-ceo-kevin-sharer-ceo-pay-report
[2] http://online.wsj.com/article/SB122098918416515871.html?mod=googlenews_wsj
[3] http://money.cnn.com/news/newsfeeds/articles/djf500/200809091331DOWJONESDJONLINE000546_FORTUNE5.htm
[4] http://www.fiercebiotech.com/special-reports/denosumab-next-gen-biotech-blockbusters
[5] http://www.fiercebiotech.com/story/amgen-s-d-mab-posts-positive-in-late-stage-trial/2008-04-03
[6] http://www.fiercebiotech.com/story/amgens-d-mab-meets-trial-goal/2008-01-25
[7] http://www.fiercebiotech.com/story/denosumab-amgens-salvation/2007-12-14